

## Acknowledgments

The following laboratories provided information about their testing services:

Baylor College of Medicine, Diagnostic Sequencing Laboratory

Benjamin B. Roa, Ph.D., Director

City of Hope Molecular Diagnostic Laboratory

Steven Sommer, M.D., Ph.D., Director

Huntington Medical Research Institutes, Molecular Oncology & Cancer Genetics Laboratory

Faye A. Eggerding, M.D., Director

Georgetown University Medical Center, Molecular Diagnostic Laboratory

Lee-Jun C. Wong, Ph.D., Director

Mayo Clinic, Molecular Genetics Laboratory

Stephen N. Thibodeau, Ph.D., Director

Memorial Sloan-Kettering Cancer Center, Diagnostic Molecular Genetics

Nathan A. Ellis, Ph.D., Director

Myriad Genetic Laboratories

Brian E. Ward, Ph.D., Director

University of Pennsylvania School of Medicine, Genetic Diagnostic Laboratory Haig Kazazian, M.D., Director

Carolyn Sue Richards, Ph.D., reviewed the manuscript and provided expert advice on technical questions about assays and quality assurance.

Philip R. Reilly, M.D, J. D., advised on the legal aspects.

Mary True provided expert editorial assistance.

## REFERENCES

- Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, *et al.* 1994. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. *Cancer Res* **54**:1645-1648.
- Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, *et al.* 1998. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. *N Engl J Med* **338**:1481-1487.
- Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. 1995. Lifetime risk of different cancers in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. *Int J Cancer* **64**:430-433.
- ACCE. Screening for ovarian or early onset breast cancer risk in women with a family history. In preparation.
- Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC. 2000. Family history-taking in community family practice: implications for genetic screening. *Genet Med* **2**:180-185.
- Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. 2001. Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. *J Med Genet* **38**:787-792.
- Aktan-Collan K, Mecklin JP, de la Chapelle A, Peltomaki P, Uutela A, Kaariainen H. 2000. Evaluation of a counseling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer. *J Med Genet* **37**:108-113.
- Andreutti-Zaugg CJ, Scott RJ, Iggo R. 1997. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. *Cancer Res* **57**:3288-3293.
- Andrykowski MA, Lightner R, Studts JL, Munn RK. 1997. Hereditary cancer risk notification and testing: how interested is the general population? *J Clin Oncol* **15**:2139-2148.
- Arber N. 2000. Do NSAIDs prevent colorectal cancer? *Can J Gastroenterol* **14**:299-307.
- Bapat BV, Madlensky L, Temple LK, Hiruki T, Redston M, Baron DL, *et al.* 1999. Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer. *Hum Genet* **104**:167-176.
- Bapat B, Noorani H, Cohen Z, Berk T, Mitri A, Gallie B, *et al.* 1999. Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis. *Gut* **44**:698-703.
- Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, *et al.* 2003. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* **348**:891-899.
- Batra S, Valdimarsdottir H, McGovern M, Itzkowitz S, Brown K. 2002. Awareness of genetic testing for colorectal cancer predisposition among specialists in gastroenterology. *Am J Gastroenterol* **97**:729-733.
- Bisgaard ML, Jager AC, Myrhoj T, Bernstein I, Nielsen FC. 2002. Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype correlation between patients with and without identified mutation. *Hum Mutat* **20**:20-27.
- Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, *et al.* 1997. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary non-polyposis colon cancer. Cancer Genetics Studies Consortium. *JAMA* **277**:915-919.
- Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, *et al.* 2000. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. *Int J Cancer* **89**:87-91.
- Chikhaoui Y, Gelinas H, Joseph L, Lance JM. 2002. Cost-minimization analysis of genetic testing versus clinical screening of at-risk relatives for familial adenomatous polyposis. *Int J Technol Assess Health Care* **18**:67-80.

- Codori AM, Zawacki KL, Petersen GM, Miglioretti DL, Bacon JA, Trimbath JD, *et al.* 2003. Genetic testing for hereditary colorectal cancer in children: long-term psychological effects. *Am J Med Genet* **116A**:117-128.
- Cromwell DM, Moore RD, Brensinger JD, Petersen GM, Bass EB, Giardiello FM. 1998. Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis. *Gastroenterology* **114**:893-901.
- Cruz-Correa M, Giardiello FM. 2002. Diagnosis and management of hereditary colon cancer. *Gastroenterol Clin North Am* **31**:537-549, x.
- Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Burgart LJ, *et al.* 2001. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. *Am J Hum Genet* **69**:780-790.
- Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J. 2000. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. *Eur J Cancer* **36**:49-54.
- de la Chapelle A. 2001. Address. American Society of Human Genetics, San Diego, October 12-16, 2001.
- de la Chapelle A. 2003a. 2002 William Allan Award Address. Inherited human diseases: victories, challenges, disappointments. *Am J Hum Genet* **72**:236-240.
- de la Chapelle A. 2003b. Microsatellite instability. *N Engl J Med* **349**:209-210.
- Dieumegard B, Grandjouan S, Sabourin JC, Le Bihan ML, Lefrere I, Bellefqih S, *et al.* 2000. Extensive molecular screening for hereditary non-polyposis colorectal cancer. *Br J Cancer* **82**:871-880.
- Eng C, Brody LC, Wagner TM, Devilee P, Vijg J, Szabo C, *et al.* 2001a. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. *J Med Genet* **38**:824-833.
- Eng C, Hampel H, de la Chapelle A. 2001b. Genetic testing for cancer predisposition. *Annu Rev Med* **52**:371-400.
- Esplen MJ, Madlensky L, Butler K, McKinnon W, Bapat B, Wong J, *et al.* 2001. Motivations and psychosocial impact of genetic testing for HNPCC. *Am J Med Genet* **103**:9-15.
- Evans DG, Wu CL, Walsh S, Hansen I, Verma L, Robinson C, *et al.* 2001. Re: Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. *J Natl Cancer Inst* **93**:716-717.
- Farrington SM, Lin-Goerke J, Ling J, Wang Y, Burczak JD, Robbins DJ, *et al.* 1998. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls. *Am J Hum Genet* **63**:749-759.
- Fearnhead NS, Britton MP, Bodmer WF. 2001. The ABC of APC. *Hum Mol Genet* **10**:721-733.
- Frazier ML, Sinicrope FA, Amos CI, Cleary KR, Lynch PM, Levin B, *et al.* 1999. Loci for efficient detection of microsatellite instability in hereditary non-polyposis colorectal cancer. *Oncol Rep* **6**:497-505.
- Frazier ML, Xi L, Zong J, Viscofsky N, Rashid A, Wu EF, *et al.* 2003. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. *Cancer Res* **63**:4805-4808.
- Frueh FW, Noyer-Weidner M. 2003. The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics. *Clin Chem Lab Med* **41**:452-461.
- Geller G, Botkin JR, Green MJ, Press N, Biesecker BB, Wilfond B, *et al.* 1997. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. *JAMA* **277**:1467-1474.

- Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon JA, *et al.* 1997. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. *N Engl J Med* **336**:823-827.
- Giardiello FM, Brensinger JD, Petersen GM. 2001. AGA technical review on hereditary colorectal cancer and genetic testing. *Gastroenterology* **121**:198-213.
- Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimpath JD, *et al.* 2002. Primary chemoprevention of familial adenomatous polyposis with sulindac. *N Engl J Med* **346**:1054-1059.
- Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, *et al.* 2000. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med* **342**:69-77.
- Guerrette S, Acharya S, Fishel R. 1999. The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. *J Biol Chem* **274**:6336-6341.
- Hadley DW, Jenkins J, Dimond E, Nakahara K, Grogan L, Liewehr DJ, *et al.* 2003. Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. *Arch Intern Med* **163**:573-582.
- Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, *et al.* 1995. The molecular basis of Turcot's syndrome. *N Engl J Med* **332**:839-47.
- Healthy People. <http://www.health.gov/healthypeople/document/HTML/Volume1/03Cancer.htm> (accessed August 11, 2004).
- Hoedema R, Monroe T, Bos C, Palmer S, Kim D, Marvin M, *et al.* 2003. Genetic testing for hereditary nonpolyposis colorectal cancer. *Am Surg* **69**:387-392.
- Jacob S, Praz F. 2002. DNA mismatch repair defects: role in colorectal carcinogenesis. *Biochimie* **84**:27-47.
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, *et al.* 2004. Cancer statistics, 2004. *CA Cancer J Clin* **54**:8-29.
- Joint Test and Technology Transfer Committee Working Group, American College of Medical Genetics, 9650 Rockville Pike, Bethesda, MD 20814-3998, United States. Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Joint Test and Technology Transfer Committee Working Group. 2000. *Genet Med* **2**:362-366.
- Katballe N, Juul S, Christensen M, Orntoft TF, Wikman FP, Laurberg S. 2001. Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. *Br J Surg* **88**:1228-1233.
- Kohonen-Corish M, Ross VL, Doe WF, Kool DA, Edkins E, Faragher I, *et al.* 1996. RNA-based mutation screening in hereditary nonpolyposis colorectal cancer. *Am J Hum Genet* **59**:818-824.
- Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. 2000. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. *Cancer Res* **60**:249-252.
- Lal G, Gallinger S. 2000. Familial adenomatous polyposis. *Semin Surg Oncol* **18**:314-323.
- Laupacis A, Feeny D, Detsky AS, Tugwell PX. 1992. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. *CMAJ* **146**:473-481.
- Lerman C, Hughes C, Trock BJ, Myers RE, Main D, Bonney A, *et al.* 1999. Genetic testing in families with hereditary nonpolyposis colon cancer. *JAMA* **281**:1618-1622.
- Liu B, Parsons R, Papadopoulos N, Nicolaidis NC, Lynch HT, Watson P, *et al.* 1996. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. *Nat Med* **2**:169-174.

- Liu T, Wahlberg S, Burek E, Lindblom P, Rubio C, Lindblom A. 2000. Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. *Genes Chromosomes Cancer* **27**:17-25.
- Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Jarvinen H, *et al.* 2001. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). *Cancer Res* **61**:4545-4549.
- Lynch HT. 1996. Is there a role for prophylactic subtotal colectomy among hereditary non-polyposis colorectal cancer germline mutation carriers? *Dis Colon Rectum* **39**:109-110.
- Lynch HT, de la Chapelle A. 1999. Genetic susceptibility to non-polyposis colorectal cancer. *J Med Genet* **36**:801-818.
- Lynch HT, Lynch JF. 2002. Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies. *Biochimie* **84**:3-17.
- Lynch HT, Lynch J. 2000. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. *J Clin Oncol* **18**:19S-31S.
- Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. 1966. Hereditary factors in cancer. Study of two large midwestern kindreds. *Arch Intern Med* **117**:206-212.
- Lynch HT, Smyrk TC. 1998. Identifying hereditary nonpolyposis colorectal cancer. *N Engl J Med* **338**:1537-1538.
- Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, *et al.* 1993. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. *Gastroenterology* **104**:1535-1549.
- Lynch HT, Watson P, Shaw TG, Lynch JF, Harty AE, Franklin BA, *et al.* 1999. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. *Cancer* **86** (Supp):2457-2463.
- Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. 2000. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. *J Clin Oncol* **18**:2484-2492.
- Mecklin JP. 1987. Frequency of hereditary colorectal carcinoma. *Gastroenterology* **93**:1021-1025.
- Michie S, Bobrow M, Marteau TM. 2001. Predictive genetic testing in children and adults: a study of emotional impact. *J Med Genet* **38**:519-526.
- Mitchell RJ, Farrington SM, Dunlop MG, Campbell H. 2002. Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: A HuGE review. *Am J Epidemiol* **156**:885-902.
- Percesepe A, Borghi F, Menigatti AM, Losi L, Foroni M, Di Gregorio C, *et al.* 2001. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. *J Clin Oncol* **19**:3944-3950.
- Petersen GM, Boyd PA. 1995. Gene tests and counseling for colorectal cancer risk: lessons from familial polyposis. *J Natl Cancer Inst Monogr* **17**:67-71.
- Pistorius SR, Kruppa C, Haas S, Plaschke J, Kruger S, Bulitta CJ, *et al.* 2000. Clinical consequences of molecular diagnosis in families with mismatch repair gene germline mutations. *Int J Colorectal Dis* **15**:255-263.
- Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics and American College of Medical Genetics Board of Directors. 1995. *Am J Hum Genet* **57**:1233-1241.
- Powe BD. 1994. Perceptions of cancer fatalism among African Americans: the influence of education, income, and cancer knowledge. *J Natl Black Nurses Assoc* **7**:41-48.
- Powell SM. 2002. Direct analysis for familial adenomatous polyposis mutations. *Mol Biotechnol* **20**:197-207.

- Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. 2001. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. *Ann Intern Med* **135**:577-588.
- Reyes CM, Allen BA, Terdiman JP, Wilson LS. 2002. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. *Cancer* **95**:1848-1856.
- Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, *et al.* 1997. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda guidelines. *J Natl Cancer Inst* **89**:1758-1762.
- Ruschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstädter F, *et al.* 1998. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. *Proc Natl Acad Sci USA* **95**:11301-11306.
- Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, *et al.* 2000. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. *J Clin Oncol* **18**:2193-2200.
- Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, *et al.* 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med* **348**: 883-890.
- Scapoli C, Ponz de Leon M, Sassatelli R, Benatti P, Roncucci L, Collins A, *et al.* 1994. Genetic epidemiology of hereditary non-polyposis colorectal cancer syndromes in Modena, Italy: results of a complex segregation analysis. *Ann Hum Genet* **58**:275-295.
- Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, *et al.* 2001. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. *Am J Hum Genet* **68**:118-127.
- Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, *et al.* 1997. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. *JAMA* **278**:1242-1250.
- Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L, *et al.* 2002. Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or "multiple" colorectal adenomas. *Proc Natl Acad Sci USA* **99**:2954-2958.
- Slattery ML, Curtin K, Anderson K, Ma K-, Ballard L, Edwards S, *et al.* 2000. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. *J Natl Cancer Inst* **92**:1831-1836.
- Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, Anderson K, *et al.* 2001a. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. *Cancer Res* **61**:126-130.
- Slattery ML, Samowitz W, Ballard L, Schaffer D, Leppert M, Potter JD. 2001b. A molecular variant of the APC gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer. *J Cancer Res* **61**:1000-1004.
- Stanley AJ, Gaff CL, Aittomaki AK, Fabre LC, Macrae FA, St John J. 2000. Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC). *Med J Aust* **172**:313-316.
- Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. 1996. *J Clin Oncol* **14**:1730-1736.
- Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. 1998. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. *Ann Intern Med* **129**:787-796.
- Trimbath JD, Giardiello FM. 2002. Review article: genetic testing and counseling for hereditary colorectal cancer. *Aliment Pharmacol Ther* **16**:1843-1857.

- Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, *et al.* 2004. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* **96**:261-268.
- Varesco L, Groden J, Spirio L, Robertson M, Weiss R, Gismondi V, *et al.* 1993. A rapid screening method to detect nonsense and frameshift mutations: identification of disease-causing APC alleles. *Cancer Res* **53**:5581-5584.
- Vasen HFA, Mecklin JP, MeeraKhan P, Lynch HT. 1991. The International Collaborative Group on Hereditary Non-polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum* **36**:424-425.
- Vasen HF, Offerhaus GJA, den Hartog Jager FC, Menko FH, Nagengast FM, Griffioen G, *et al.* 1990. The tumour spectrum in hereditary nonpolyposis colorectal cancer: A study of 24 kindreds in the Netherlands. *Int J Cancer* **46**:31-34, 1990.
- Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G, *et al.* 1998. A cost-effectiveness analysis of colorectal screening for hereditary nonpolyposis colorectal carcinoma gene carriers. *Cancer* **82**:1632-1637.
- Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, *et al.* 1996. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology* **110**:1020-1027.
- Vernon SW, Gritz ER, Peterson SK, Amos CI, Perz CA, Baile WF, *et al.* 1997. Correlates of psychologic distress in colorectal cancer patients undergoing genetic testing for hereditary colon cancer. *Health Psychol* **16**:73-86.
- Vernon SW, Gritz ER, Peterson SK, Perz CA, Marani S, Amos CI, *et al.* 1999. Intention to learn results of genetic testing for hereditary colon cancer. *Cancer Epidemiol Biomarkers Prevent* **8**:353-360.
- Villejo LA. Patient education for Hispanic cancer patients. In L.A. Jon (Ed), *Minorities and Cancer*, New York:Springer-Verlag, pp 295-300, 1989.
- Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P, *et al.* 2003. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: High mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. *Am J Hum Genet* **72**:1088-1100.
- Watson P, Lynch HT. 1993. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* **71**:677-685.
- Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. 1994. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. *Am J Med* **96**:516-520.
- Whiteside D, McLeod R, Graham G, Steckley JL, Booth K, Somerville MJ, *et al.* 2002. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-au-lait spots. *Cancer Res* **62**:359-362.
- Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, *et al.* 1998. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. *N Engl J Med* **339**:511-518.
- Wikman FP, Katballe N, Christensen M, Laurberg S, Orntoft TF. 2000. Efficient mutation detection in mismatch repair genes using a combination of single-strand conformational polymorphism and heteroduplex analysis at a controlled temperature. *Genet Test* **4**:15-21.
- Wilson JMG, Jungner F. Principles and practice of screening for disease (Public Health Papers No.1 34). WHO, Geneva, 1968.
- Wong N, Lasko D, Rabelo R, Pinsky L, Gordon PH, Foulkes W. 2001. Genetic counseling and interpretation of genetic tests in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. *Dis Colon Rectum* **44**:271-279.
- Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai K. 1999. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. *Int J Cancer* **84**:400-403.

- Yan H, Papadopoulos N, Marra G, Perrera C, Jiricny J, Boland CR, *et al.* 2000. Conversion of diploidy to haploidy. *Nature* **403**:723-724.
- Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, Faucett A, Khoury MJ. 2002. Can family history be used as a tool for public health and preventive medicine? *Genet Med* **4**:304-310.
- Ziogas A, Anton-Culver H. 2003. Validation of family history data in cancer family registries. *Am J Prev Med* **24**:190-199.

DRAFT